Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
出版年份 2020 全文链接
标题
Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)
作者
关键词
-
出版物
MOLECULES
Volume 25, Issue 11, Pages 2666
出版商
MDPI AG
发表日期
2020-06-09
DOI
10.3390/molecules25112666
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors
- (2020) Nadia Y. Megally Abdo et al. BIOORGANIC CHEMISTRY
- c-Met as a new marker of cellular senescence
- (2019) Maria Boichuck et al. Aging-US
- Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors
- (2019) Xiang Nan et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors
- (2019) Mohamed A. Zeidan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2
- (2019) Dengshuai Wei et al. BIOORGANIC CHEMISTRY
- Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors
- (2019) Arpita Desai et al. Future Oncology
- Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives as Potent c-Met Kinase Inhibitor
- (2019) Yifeng Yang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice
- (2019) Haoru Fan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development
- (2019) Lin-Sheng Zhuo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking
- (2019) Eman M. Ahmed et al. BIOORGANIC CHEMISTRY
- Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase
- (2019) Xu Yuan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors
- (2019) Heba T. Abdel-Mohsen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model
- (2019) Velma Ganga Reddy et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC
- (2019) Eman M.E. Dokla et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold
- (2019) Ming-Shu Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells
- (2018) Alexei A. Goltsov et al. ANNALS OF THORACIC SURGERY
- Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met
- (2018) Heba A. Ibrahim et al. BIOORGANIC CHEMISTRY
- Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET
- (2018) Pankaj Kumar Singh et al. BIOORGANIC CHEMISTRY
- Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors
- (2018) Wuji Sun et al. BIOORGANIC CHEMISTRY
- Vascular endothelial growth factor signaling in development and disease
- (2018) Sinem Karaman et al. DEVELOPMENT
- Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
- (2018) Ana M. Molina et al. EUROPEAN JOURNAL OF CANCER
- Synthesis and bioevaluation and doking study of 1 H -pyrrolo[2,3- b ]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors
- (2018) Wenhui Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Dual or multi-targeting inhibitors: The next generation anticancer agents
- (2018) Nulgumnalli Manjunathaiah Raghavendra et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, biological evaluation and molecular modeling of novel 1 H -pyrazolo[3,4-d]pyrimidine derivatives as BRAF V600E and VEGFR-2 dual inhibitors
- (2018) Yuanyuan Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis and molecular modeling study for some new 2-substituted benzimidazoles as dual inhibitors for VEGFR-2 and c-Met
- (2018) Heba A Ibrahim et al. Future Medicinal Chemistry
- Structure activity relationships of chrysoeriol and analogs as dual c‑Met and VEGFR2 tyrosine kinase inhibitors
- (2018) Shuang Lai et al. ONCOLOGY REPORTS
- Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2
- (2018) Wei Shi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of novel 6,11-dihydro-5 H -benzo[e]pyrimido- [5,4- b ][1,4]diazepine derivatives as potential c-Met inhibitors
- (2017) Daowei Huang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Identification of 3-substituted-6-(1-(1 H -[1,2,3]triazolo[4,5- b ]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization
- (2017) Fei Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors
- (2017) Lin Xiao Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4
- (2017) Chuansheng Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)
- (2017) Fan-Wei Peng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives
- (2017) Dong Lu et al. ACS Medicinal Chemistry Letters
- Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
- (2017) Natalie Rothenberger et al. Cancers
- The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches
- (2017) Chi-Tan Hu et al. Cancers
- Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors
- (2016) Xin Zhai et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of 4-aminopyrimidine-5-cabaldehyde oximes as dual inhibitors of c-Met and VEGFR-2
- (2016) Hao Qiang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors
- (2016) Qidong Tang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs
- (2016) Jin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors
- (2016) Ju Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Sustained inhibition of cMET-VEGFR2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer
- (2016) Ashish A. Kulkarni et al. Nanomedicine-Nanotechnology Biology and Medicine
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
- (2016) Beverly L. Falcon et al. PHARMACOLOGY & THERAPEUTICS
- Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
- (2015) Dieter Dorsch et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2
- (2014) Lei Shi et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of novel type II c-Met inhibitors based on BMS-777607
- (2014) Wei Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
- (2014) Mohammad Hojjat-Farsangi INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity
- (2014) Zhengsheng Zhan et al. ACS Medicinal Chemistry Letters
- RON confers lapatinib resistance in HER2-positive breast cancer cells
- (2013) Quanren Wang et al. CANCER LETTERS
- Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
- (2013) J. Jean Cui JOURNAL OF MEDICINAL CHEMISTRY
- Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment
- (2013) Y Kwon et al. ONCOGENE
- Discovery of Plumericin as a novel potent NF-κB inhibitor from Himatanthus sucuuba
- (2013) N Fakhrudin et al. PLANTA MEDICA
- Associations of VEGF/VEGF-Receptor and HGF/c-Met Promoter Polymorphisms With Progression/Regression of Retinopathy of Prematurity
- (2012) Mahmut Kaya et al. CURRENT EYE RESEARCH
- Higher Levels of c-Met Expression and Phosphorylation Identify Cell Lines With Increased Sensitivity to AMG-458, a Novel Selective c-Met Inhibitor With Radiosensitizing Effects
- (2012) Bo Li et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
- (2011) J.- C. Soria et al. ANNALS OF ONCOLOGY
- Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis
- (2011) M. Zillhardt et al. CLINICAL CANCER RESEARCH
- Recent Advances in Antiangiogenic Agents with VEGFR as Target
- (2011) J. Zhang et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- 106 Preclinical studies and characterization of BMS-794833, a small molecule inhibitor of Met and VEGFR-2 kinases
- (2010) J. Fargnoli et al. EJC SUPPLEMENTS
- Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
- (2010) D. Xu et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search